CLASS II ONGOING Drug recall · Reported 12 Jun 2024 · FDA Enforcement Report

Rizatriptan Benzoate Orally Disintegrating Tablets recalled

Glenmark Pharmaceuticals Inc., U is recalling Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg, 18-Dose Tablets, distributed nationwide in the US. The recall was initiated on 13 May 2024 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot#: 19223402; Exp. 7/2024 Lot#: 19224858; Exp. 11/2024 Lot#: 19232492; Exp. 6/2025
NDC68462-467, 68462-468
UPC0368462467060, 0368462468067
Quantity recalled13296 cartons

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0535-2024
FDA event ID
94608
Recalling firm
Glenmark Pharmaceuticals Inc., U, Mahwah, NJ
Manufacturer
Glenmark Pharmaceuticals Inc., USA
Classification
Class II
Status
Ongoing
Recall initiated
13 May 2024
FDA classified
4 Jun 2024
Reported
12 Jun 2024
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Nitrosamine Impurity

Timeline

13 May 2024Recall initiated by company
4 Jun 2024Classified by FDA+22 days
12 Jun 2024Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Nitrosamines are impurities that can form during drug manufacturing or storage. Above the FDA acceptable intake limit, long-term exposure may raise cancer risk. The FDA advises patients to keep taking the medicine until they have a replacement.

Product as listed by the FDA

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-468-06

Where it was distributed

US Nationwide.

Nationwide

Questions about this recall

Is Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg, 18-Dose Tablets recalled?

Yes. Glenmark Pharmaceuticals Inc., U recalled Rizatriptan Benzoate Orally Disintegrating Tablets, USP 10mg, 18-Dose Tablets on 13 May 2024. The recall is Class II and its status is Ongoing. Recall number D-0535-2024.

Why was it recalled?

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Which lots are affected?

Lot#: 19223402; Exp. 7/2024 Lot#: 19224858; Exp. 11/2024 Lot#: 19232492; Exp. 6/2025

Where was it sold?

US Nationwide.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Glenmark Pharmaceuticals Inc., U

All 141

Other Rizatriptan Benzoate recalls

All 8